Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Kymera Therapeutics Ownership Summary

Kymera Therapeutics is owned by 90.59% institutional investors, 1.27% insiders, and 8.13% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.78% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Kymera Therapeutics	90.59%	1.27%	8.13%
Sector	Healthcare Stocks	88.01%	8.90%	3.09%
Industry	Biotech Stocks	109.70%	8.77%	-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Price t rowe associates inc /md/	6.39M	9.03%	$190.76M
Baker bros. advisors lp	6.00M	8.47%	$178.98M
Atlas venture life science advisors	5.35M	7.56%	$159.71M
Bvf inc/il	5.16M	7.29%	$154.08M
Fmr	4.83M	6.82%	$144.08M
Vanguard group	4.82M	6.81%	$143.95M
Wellington management group llp	4.31M	6.09%	$128.64M
Blackrock	4.16M	5.87%	$124.04M
Avoro capital advisors	3.89M	5.50%	$116.08M
Artal group	3.01M	4.25%	$89.72M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Atlas venture life science advisors	5.35M	16.82%	$159.71M
Aquilo capital management	328.74K	9.46%	$9.81M
Bvf inc/il	5.16M	4.32%	$154.08M
Redmile group	1.58M	2.85%	$47.14M
Deer management	415.89K	2.55%	$12.41M
Artal group	3.01M	2.29%	$89.72M
Baker bros. advisors lp	6.00M	2.29%	$178.98M
Avoro capital advisors	3.89M	1.55%	$116.08M
Deep track capital, lp	1.50M	1.34%	$44.77M
Propel bio management	56.36K	1.09%	$1.68M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.16M	0.00%	499.77K
Fmr	4.83M	0.01%	462.43K
Eventide asset management	462.10K	0.24%	442.32K
Ubs asset management americas	433.57K	0.00%	253.63K
Deep track capital, lp	1.50M	1.34%	237.75K

Top Sellers

Holder	Shares	% Assets	Change
State street	1.91M	0.00%	-761.83K
Jpmorgan chase	44.94K	0.00%	-410.99K
Rock springs capital management lp	1.16M	1.05%	-358.26K
Barclays	49.09K	0.00%	-270.81K
Citigroup	19.59K	0.00%	-201.32K

New Positions

Holder	Shares	% Assets	Change	Value
Driehaus capital management	223.41K	0.06%	223.41K	$6.67M
Norges bank	117.88K	0.00%	117.88K	$3.52M
Capital fund management	29.95K	0.00%	29.95K	$894.07K
Mirae asset global etfs	24.57K	0.00%	24.57K	$734.68K
Corebridge financial	23.93K	0.00%	23.93K	$714.34K

Sold Out

Holder	Change
Financial gravity asset management	-2.00
Riggs asset managment	-7.00
Nelson, van denburg & campbell wealth management group	-8.00
Cva family office	-12.00
Continuum advisory	-13.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	181	16.03%	68,964,551	2.37%	90	1.00%	93	6.90%	62	31.91%
Jun 30, 2024	155	-4.32%	67,367,833	0.44%	95	0.72%	86	-14.85%	47	11.90%
Mar 31, 2024	162	20.00%	67,073,034	11.04%	114	1.07%	101	48.53%	42	-17.65%
Dec 31, 2023	135	10.66%	60,406,777	5.38%	103	1.07%	68	11.48%	51	45.71%
Sep 30, 2023	122	-6.87%	57,323,132	-1.85%	98	0.98%	61	-8.96%	35	6.06%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
US Small-Cap Growth II Equity Comp	3.09M	4.78%	-46.89K
T. Rowe Price New Horizons	3.09M	4.78%	-
Fidelity Growth Compy Commingled Pl S	2.27M	3.50%	3.10K
Fidelity Growth Compy Commingled Pl O	2.24M	3.46%	52.60K
Vanguard Health Care Inv	1.83M	2.82%	378.94K
Fidelity Growth Company Fund	1.65M	2.54%	-4.02K
Vanguard Total Stock Mkt Idx Inv	1.53M	2.36%	2.50K
T. Rowe Price Health Sciences	1.37M	2.12%	124.68K
iShares Russell 2000 ETF	1.26M	1.95%	-4.85K
Vanguard Small Cap Index	1.24M	1.91%	19.68K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 06, 2025	Chiniara Ellen	Chief Legal Officer	Sell	$130.64K
Dec 02, 2024	Esposito Pamela	-	Sell	$122.50K
Sep 17, 2024	Esposito Pamela	-	Sell	$303.18K
Sep 17, 2024	Esposito Pamela	-	Sell	$348.58K
Aug 26, 2024	Albers Jeffrey W.	-	Sell	$245.51K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	1
2024 Q3	5	16
2024 Q2	-	9
2024 Q1	3	49
2023 Q4	6	-

KYMR Ownership FAQ

Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 90.59%, followed by 1.27% insiders and 8.14% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 109.70%, which Kymera Therapeutics falls below.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (6.39M shares, 9.03%), Baker bros. advisors lp (6M shares, 8.47%), and Atlas venture life science advisors (5.35M shares, 7.56%). Together, they hold 25.06% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 16.82% of its assets in 5.35M Kymera Therapeutics shares, valued at 159.71M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Kymera Therapeutics shares, with 4.78% of its total shares outstanding invested in 3.09M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools